tbuckley/cabot-search huggingface dataset:
THE IMPORTANCE OF CLOTHING IN WAR.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sore Throat
Authors: I. H. J. Bourne
Journal: BMJ (1955)

<h3>ABSTRACT</h3> Third generation Hepatitis C virus (HCV) NS3/4A protease inhibitors (PIs), glecaprevir and voxilaprevir, are highly effective across genotypes and against many resistant variants. Unlike earlier PIs, these compounds have fluorine substitutions on the P2-P4 macrocycle and P1 moieties. Fluorination has long been used in medicinal chemistry as a strategy to improve physicochemical properties and potency. However, the molecular basis by which fluorination improves potency and resistance profile of HCV NS3/4A PIs is not well understood. To systematically analyze the contribution of fluorine substitutions to inhibitor potency and resistance profile, we used a multi-disciplinary approach involving inhibitor design and synthesis, enzyme inhibition assays, co-crystallography, and structural analysis. A panel of inhibitors in matched pairs were designed with and without P4 cap fluorination, tested against WT protease and the D168A resistant variant, and a total of 22 high-resolution co-crystal structures were determined. While fluorination did not significantly improve potency against the WT protease, PIs with fluorinated P4 caps retained much better potency against the D168A protease variant. Detailed analysis of the co-crystal structures revealed that PIs with fluorinated P4 caps can sample alternate binding conformations that enable adapting to structural changes induced by the D168A substitution. Our results elucidate molecular mechanisms of fluorine-specific inhibitor interactions that can be leveraged in avoiding drug resistance.
TULAREMIA
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thrombotic thrombocytopenic purpura-like syndrome associated with infective endocarditis. A possible immune complex disorder
Authors: A. S. Bayer
Journal: JAMA (1977)

A thrombotic thrombocytopenic purpura (TTP)-like syndrome was the chief presenting feature in two patients with infective endocarditis. Clinical and laboratory aberrations of the syndrome were rapidly reversed by specific antimicrobial therapy. Hypocomplementemia and high levels of circulating immune complexes were detected initially in both patients. Because these returned to normal as the TTP syndrome abated, an immunopathologic mechanism may have been operative. (<i>JAMA</i>238:408-410, 1977)
Notice to Readers: Newly Licensed Smallpox Vaccine to Replace Old Smallpox Vaccine
Journal: JAMA (2008)

evidence of immunity, born before 1957, or documentation of physiciandiagnosed measles) should be restricted from entering the rooms of patients known or suspected to have measles. 4,10 The examination room should not be used for 2 hours after the infectious patient leaves.Suspected measles patients should not be referred to other locations for laboratory tests unless infection-control measures can be implemented at those locations.Measles morbidity and mortality can be reduced through vaccination with MMR vaccine.Vaccination of U.S. travelers can reduce measles importations.Sustained high population immunity through vaccination, effective surveillance, and robust public health preparedness and response capacity are needed to keep the United States free from indigenous measles transmission and control any outbreaks associated with importations.
Persistent high fibrinogen levels at late follow-up of percutaneous coronary intervention are associated with clinical restenosis Jean-Philipe Collet, I. Sotirov, C. Lesty, R. Choussat, A. Ankri, G. Drobinski, D. Thomas, G. Montalescot. Piti�-Salp�tri�re Hospital-Department of Cardiology, Paris (75013), France
Journal: Journal of the American College of Cardiology (2001)
AZT (zidovudine) just a step away from FDA approval for AIDS therapy
Authors: C. Marwick
Journal: JAMA (1987)

AN ADVISORY COMMITTEE of the Food and Drug Administration (FDA), by a vote of ten to one, has recommended that the FDA commissioner approve the anti-viral drug azidothymidine (AZT) for the treatment of acquired immunodeficiency syndrome (AIDS). The United States Adopted Name (USAN) designation for AZT, decided upon earlier this year, is zidovudine. The drug has been shown to inhibit the enzyme that the AIDS virus uses to replicate in the cell. It also appears to have other advantages in the management of patients with AIDS, such as the ability to penetrate the blood-brain barrier. The committee's action is not binding on the agency, but such advice always carries considerable weight. Given the present poor outlook for patients with AIDS and the lack of effective treatment for the disease, the agency is unlikely to reject the committee's recommendation. Yet, even when approved, AZT will be restricted to those groups of
Randomized trial of a smartphone mobile app for adherence to oral chemotherapy.
Authors: Joseph Greer, Jamie M. Jacobs, Nicole Pensak, Lauren Ellen Nisotel, Joel Fishbein, James MacDonald, Molly Ream, Charn-Xin Fuh, Joanne S Buzaglo, Alona Muzikansky, Inga Tolin Lennes, Steven Safren, William F. Pirl, Jennifer S. Temel
Journal: Journal of Clinical Oncology (2017)

10055 Background: As patients with cancer are increasingly prescribed oral chemotherapy, they share greater responsibility for ensuring adherence and monitoring side effects. The aim of this study was to test the effect of a smartphone mobile app to improve adherence and symptom management in patients prescribed oral chemotherapy. Methods: From 2/15 to 12/16, 181 patients with diverse cancers prescribed oral chemotherapy were randomized to receive either the smartphone mobile app or standard care. The mobile app included a medication treatment plan with alerts, symptom reporting module, education library, and cancer-specific resources. The primary outcome was adherence, measured by electronic pill cap (MEMS) and self-report (Morisky Medication Adherence Scale; MMAS). To assess symptoms, mood, and satisfaction with care, participants completed the MD Anderson Symptom Inventory, Hospital Anxiety &amp; Depression Scale (HADS); and Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction (FACIT-TS) at baseline and 12 weeks. General linear models were used to assess intervention effects on patient outcomes. Results: Study groups did not differ across outcome measures from baseline to week 12. Secondary analyses showed that baseline adherence (MMAS) and anxiety (HADS) were moderators of intervention effects on adherence and treatment satisfaction. Among patients who reported adherence problems, those assigned to the mobile app had better average MEMS adherence (Mean Diff = 19.30, 95% CI = 0.09-38.51, p = .05) and satisfaction with clinician explanations per the FACIT-TS (Mean Diff = 1.69, 95% CI = 0.25-3.13, p = .02) compared to standard care. Also, among patients with higher anxiety, those in the mobile app group reported better adherence on the 12-week MMAS (95.2% vs. 68.0%, OR = 0.11, 95% CI = 0.01, 0.94, p = .04) and satisfaction with interpersonal treatment per the FACIT-TS (Mean Diff = 0.76, 95% CI = 0.13-1.39, p = .02) compared to standard care. Conclusions: Although potentially not for everyone taking oral chemotherapy, a smartphone mobile app to improve adherence and treatment satisfaction may be useful for patients with certain risk factors, such as those struggling with adherence or anxiety. Clinical trial information: NCT02157519.
Emergency Medicine
Authors: Jerris R. Hedges
Journal: JAMA (1990)

The field of emergency medicine encompasses the provision of care to acutely ill and injured patients in both the community (prehospital) and hospital (emergency department) settings. While the initial ambulatory and critical care provided by the emergency physician overlaps that of other clinical specialties, the practice of emergency care is characterized by an unselected patient population, 24-hour availability, and the simultaneous management of multiple patients with varying presentations and degrees of illness or injury. For much of modern society's mobile population, emergency medicine offers the primary portal for accessing the health care system. The emergency physician must provide an effective interface between the patient and the physician(s) who will provide the patient's subsequent care. Recognition of the unique knowledge base and clinical skills needed for the practice of emergency medicine led the American Board of Medical Specialties to recognize the American Board of Emergency Medicine as a primary board in
AIDS, Neurology
Authors: Russell E. Bartt
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
* Red cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding- a survey of 815 clinicians
Authors: V. Jairath, B. Kahan, R. Logan, K. Palmer, S. Travis, M. Murphy
Journal: Gut (2011)

<h3>Introduction</h3> Acute Upper Gastrointestinal Bleeding (AUGIB) accounts for 14% of all red blood cell (RBC) transfusions in England. Studies of RBC transfusion practice in critical care and cardiac surgery have shown widespread practice variation. Since there are no such data in AUGIB and, as a consequence of recent evidence that early transfusion is associated with adverse outcomes in AUGIB,1 the current study was designed to assess attitudes towards RBC transfusion practice in patients presenting with AUGIB. <h3>Methods</h3> A survey depicting six vignettes representing a range of clinical scenarios in AUGIB were piloted for content and emailed to practicing consultants and registrars in gastroenterology, acute medicine and upper gastrointestinal surgery through their member organisations. Respondents were asked to select a haemoglobin (Hb) trigger at which they would ordinarily transfuse red blood cells. Results were analysed using proportional odds models and robust standard errors were used to account for clustering. <h3>Results</h3> The overall response rate was 48% (815/1709). Transfusion triggers differed significantly between all six scenarios (p&lt;0.001). A Hb trigger &gt;9g/dl was chosen by only 13.3% of respondents to scenario 2 (young patient with features of shock). In comparison, a Hb trigger of &gt;9 g/dl was chosen for 45.2% of respondents in scenario 4 representing an older patient with ischemic heart disease. &lt;4% of clinicians reported that they would ever transfuse at a Hb trigger of &gt;10 g/dl in all scenarios. The selected Hb trigger differed between clinical specialities. Surgeons selected a lower Hb transfusion trigger than physicians across all 6 scenarios (<i>p</i>&lt;0.005), as did clinicians who had graduated within the past 5 years(<i>p</i>&lt;0.05 compared to graduants &gt;5 years). Only 70% of respondents reported familiarity with national guidelines for AUGIB. Most clinicians favoured a restrictive approach to transfusion, which is in part discordant with actual transfusion practice observed in the UK National Audit of AUGIB, where 15% of all early RBC transfusions were administered to patients with a Hb &gt;10g/dL (38% of whom were haemodynamically stable) and to 50% of admissions with a presenting Hb 8.1–10 g/dl and haemodynamic stability. <h3>Conclusion</h3> There is widespread variation in attitudes towards RBC transfusion for AUGIB. Both clinician and patient characteristics influence RBC transfusion decisions. Clinical studies are needed to evaluate the safety and efficacy of differing blood transfusion strategies in AUGIB.
Active Oxygen Species in DNA Damage Induced by Carcinogenic Metal Compounds
Authors: Shosuke Kawanishi, Sumiko Inoue, Koji Yamamoto
Journal: Environmental Health Perspectives (1994)

Some carcinogenic metal compounds [chromate(VI), Fe(lil) nitrilotriacetate, cobalt(lIl), and nickel(ll)] induced formation of various oxygen radical species in the presence of hydrogen peroxide.These oxygen radicals were suggested to give different kinds of site-specific DNA damage; 8- hydroxyl-2'-deoxyguanosine formation is included in the DNA damage.Using pulsed-field gel electrophoresis, nickel sulfide was shown to induce oxidative DNA cleavage in cultured cells.On the basis of these findings, we have emphasized the role of oxygen radicals in metal carcinogenesis.
Cranioplasty in Craniopagus Twins
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical education programs sponsored by government agencies
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The E-Screen Assay: A Comparison of Different MCF7 Cell Stocks
Authors: Mercedes Villalobos, Nicolas Olea, Jose Antonio Brotons, Maria Fatima Olea-Serrano, J. Mariano Ruiz de Almodovar, Vicente Pedraza
Journal: Environmental Health Perspectives (1995)

MCF7 human breast cancer cells have been studied extensively as a model for hormonal effects on breast cancer cell growth and specific protein synthesis. Because the proliferative effect of natural estrogen is considered the hallmark of estrogen action, it was proposed that this property be used to determine whether a substance is an estrogen. The E-screen assay, developed for this purpose, is based on the ability of MCF7 cells to proliferate in the presence of estrogens. The aim of our study was to characterize the response of four MCF7 cell stocks (BUS, ATCC, BB, and BB104) and determine which of them performed best in the E-screen test. The four stocks assayed were distinguishable by their biological behavior. In the absence of estrogen, MCF7 BUS cells stopped proliferating and accumulated in the G0/G1 phase of the cell cycle; estrogen receptors increased, progesterone receptors decreased, and small amounts of pS2 protein were secreted. Of all the MCF7 stocks tested, MCF7 BUS cells showed the highest proliferative response to estradiol-17 beta: cell yields increased up to sixfold over those of nontreated cells in a 144-hr period. The differences between estrogen-supplemented and nonsupplemented MCF7 BUS cells were due mostly to G0/G1 proliferative arrest mediated by charcoal dextran-stripped serum. MCF7 BUS cell stocks and others showing a similar proliferative pattern should be chosen for use in the E-screen test, or whenever a proliferative effect of estrogen is to be demonstrated.
Grundlegende Untersuchungen für die Angioarchitektonik des menschlichen Gehirns.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Anticardiolipin antibodies in chronic hepatitis C: Implication of hepatitis C virus as the cause of the antiphospholipid syndrom
Authors: J Prieto
Journal: Hepatology (1996)

Antiphospholipid antibodies are a type of autoantibodies that have been implicated in the occurrence of thrombocytopenia and thrombotic events and have been described in autoimmune disorders and diverse viral diseases. In this study anticardiolipin antibodies (immunoglobulin G [IgG] isotype) were determined in serum from 100 patients with chronic hepatitis C and 52 healthy controls. In addition, hepatitis C virus (HCV) markers (anti-HCV and HCV RNA) were investigated in 73 patients with thrombotic disorders and no clinical evidence of liver disease; of these patients 37 cases tested negatively for anticardiolipin antibodies and 36 positively. Anticardiolipin test was positive more frequently (22%) in the group of patients with chronic hepatitis C than in healthy controls (1.9%; P < .001). Using conditional logistic-regression analysis we found that in hepatitis C patients the presence of thrombocytopenia, portal hypertension and the existence of prior thrombotic episodes were significantly related to positivity for anticardiolipin antibodies (P < .05 in all cases). In patients with no evidence of liver disease and a history of thrombotic events, hepatitis C markers were absent in all cases who tested negatively for anticardiolipin antibodies (n = 37), but were present in 16.7% of those positive for anticardiolipin (n = 36) (P = .01). In conclusion, anticardiolipin antibodies are frequently found in patients with chronic hepatitis C and in these patients they may be implicated in the occurrence of thrombosis and in the development of thrombocytopenia. Occult HCV infection is present in a significant proportion of patients with thrombotic disorders and positive for anticardiolipin (the antiphospholipid syndrome).